Iimura O, Shimamoto K, Ura N, Nakagawa M, Nishimiya T, Ando T, Yamaguchi Y, Masuda A, Ogata H, Saito S
Second Department of Internal Medicine, Sapporo Medical College, Japan.
Agents Actions Suppl. 1987;22:247-56. doi: 10.1007/978-3-0348-9299-5_26.
In order to clarify the relationship and the pathophysiological role of renal dopamine, kallikrein-kinin and prostaglandin systems in essential hypertensives, the effects of dopamine on these systems and renal sodium handling were investigated. Basal levels of kallikrein, kinin and prostaglandin E2 in essential hypertensives were significantly lower than those in normotensives. Those of kallikrein and kinin were obviously more suppressed in the low renin group than in the normal renin group, but no significant difference in prostaglandin E2 was found in either subgroup. Urinary dopamine excretion was significantly lower in the low renin essential hypertensives, while no significant difference was found between normotensives and normal renin essential hypertensives. Kallikrein activity and prostaglandin E2 were significantly increased in essential hypertensives by dopamine infusion, and no significant difference was found in kallikrein-quantity and kinin between normotensives and essential hypertensives after the infusion. These increases of kallikrein and kinin were significantly higher in the low renin group than in normal renin group, but those of prostaglandin E2 were not. Urine volume, urinary sodium excretion and fractional excretions of sodium and inorganic phosphorus were all increased in both normotensives and essential hypertensives after dopamine infusion. The increases of these were significantly greater in essential hypertensives than in normotensives, and greater in the low renin group than the normal renin group. From these results, it was suggested that the dopamine, kallikrein-kinin and prostaglandin E2 system have a close relationship with each other, and the suppression of these systems may contribute to the pathophysiology of essential hypertension, especially in the low renin group.
为了阐明原发性高血压患者肾多巴胺、激肽释放酶 - 激肽和前列腺素系统之间的关系及其病理生理作用,研究了多巴胺对这些系统及肾脏钠代谢的影响。原发性高血压患者激肽释放酶、激肽和前列腺素E2的基础水平显著低于血压正常者。低肾素组激肽释放酶和激肽的基础水平明显比正常肾素组受到更明显的抑制,但两个亚组的前列腺素E2水平均无显著差异。低肾素原发性高血压患者尿多巴胺排泄显著降低,而血压正常者与正常肾素原发性高血压患者之间未发现显著差异。原发性高血压患者静脉输注多巴胺后,激肽释放酶活性和前列腺素E2显著增加,输注后血压正常者与原发性高血压患者的激肽释放酶量和激肽水平无显著差异。低肾素组激肽释放酶和激肽的增加显著高于正常肾素组,但前列腺素E2的增加并非如此。静脉输注多巴胺后,血压正常者和原发性高血压患者的尿量、尿钠排泄以及钠和无机磷的分数排泄均增加。原发性高血压患者这些指标的增加显著大于血压正常者,且低肾素组大于正常肾素组。从这些结果推测,多巴胺、激肽释放酶 - 激肽和前列腺素E2系统相互之间关系密切,这些系统的抑制可能在原发性高血压的病理生理过程中起作用,尤其是在低肾素组。